298 related articles for article (PubMed ID: 25555914)
1. Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.
Savolainen MH; Yan X; Myöhänen TT; Huttunen HJ
J Biol Chem; 2015 Feb; 290(8):5117-5126. PubMed ID: 25555914
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
3. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
[TBL] [Abstract][Full Text] [Related]
4. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
Myöhänen TT; Norrbacka S; Savolainen MH
Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
[TBL] [Abstract][Full Text] [Related]
5. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT
Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211
[TBL] [Abstract][Full Text] [Related]
6. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
Dokleja L; Hannula MJ; Myöhänen TT
Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
[TBL] [Abstract][Full Text] [Related]
8. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
[TBL] [Abstract][Full Text] [Related]
9. Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.
Cui H; Kilpeläinen T; Zouzoula L; Auno S; Trontti K; Kurvonen S; Norrbacka S; Hovatta I; Jensen PH; Myöhänen TT
J Cell Mol Med; 2021 Oct; 25(20):9634-9646. PubMed ID: 34486218
[TBL] [Abstract][Full Text] [Related]
10. Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.
Svarcbahs R; Julku UH; Norrbacka S; Myöhänen TT
Sci Rep; 2018 Jan; 8(1):1552. PubMed ID: 29367610
[TBL] [Abstract][Full Text] [Related]
11. New tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseases.
Svarcbahs R; Julku U; Kilpeläinen T; Kyyrö M; Jäntti M; Myöhänen TT
Biochem Pharmacol; 2019 Mar; 161():113-120. PubMed ID: 30660495
[TBL] [Abstract][Full Text] [Related]
12. Inhibition-mediated changes in prolyl oligopeptidase dynamics possibly related to α-synuclein aggregation.
Walczewska-Szewc K; Rydzewski J; Lewkowicz A
Phys Chem Chem Phys; 2022 Feb; 24(7):4366-4373. PubMed ID: 35112120
[TBL] [Abstract][Full Text] [Related]
13. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy.
Cui H; Norrbacka S; Myöhänen TT
Biochem Pharmacol; 2022 Mar; 197():114899. PubMed ID: 34968496
[TBL] [Abstract][Full Text] [Related]
14. Prolyl oligopeptidase inhibition reduces oxidative stress via reducing NADPH oxidase activity by activating protein phosphatase 2A.
Eteläinen T; Kulmala V; Svarcbahs R; Jäntti M; Myöhänen TT
Free Radic Biol Med; 2021 Jun; 169():14-23. PubMed ID: 33838285
[TBL] [Abstract][Full Text] [Related]
15. Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease.
Kilpeläinen TP; Pätsi HT; Svarcbahs R; Julku UH; Eteläinen TS; Cui H; Auno S; Sipari N; Norrbacka S; Leino TO; Jäntti M; Myöhänen TT; Wallén EAA
J Med Chem; 2023 Jun; 66(11):7475-7496. PubMed ID: 37248563
[TBL] [Abstract][Full Text] [Related]
16. Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A.
Svarcbahs R; Jäntti M; Kilpeläinen T; Julku UH; Urvas L; Kivioja S; Norrbacka S; Myöhänen TT
Pharmacol Res; 2020 Jan; 151():104558. PubMed ID: 31759088
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease.
Tenreiro S; Reimão-Pinto MM; Antas P; Rino J; Wawrzycka D; Macedo D; Rosado-Ramos R; Amen T; Waiss M; Magalhães F; Gomes A; Santos CN; Kaganovich D; Outeiro TF
PLoS Genet; 2014 May; 10(5):e1004302. PubMed ID: 24810576
[TBL] [Abstract][Full Text] [Related]
18. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
[TBL] [Abstract][Full Text] [Related]
19. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
[TBL] [Abstract][Full Text] [Related]
20. Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease.
Gonçalves SA; Outeiro TF
Small GTPases; 2017 Apr; 8(2):78-84. PubMed ID: 27314512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
